KRT88P and COVID-19: HBsAg-negative/anti-HBc-positive patients with COVID-19 are at low risk of HBV reactivation during immunosuppression since this treatment does not include anti-CD20 agents [8,14,15,20,23,29,32,33,34,35,36].